Bone Biologics Corp (NASDAQ:BBLG) does about 2.13M shares in volume on a normal day but saw 159147308 shares change hands in the recent trading day. The company now has a market cap of 1.00M USD. Its current market price is $1.89, marking an increase of 136.25% compared to the previous close of $0.80. The 52 week high reached by this stock is $10.56 whilst the lowest price level in 52 weeks is $0.80.
Bone Biologics Corp (BBLG) has a 20-day trading average at $1.3462 and the current price is -82.10% off the 52-week high compared with 136.25% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.5009 and its 200-day simple moving average is $2.3044. If we look at the stock’s price movements over the week, volatility stands at 32.18%, which decreases to 16.86% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 60.94 to suggest the stock is neutral.
The consensus objective for the share price is $16.75, suggesting that the stock has a potential upside of 88.72% over the period.
The current price level is 42.46%, 27.13%, and -18.25% away from its SMA20, SMA50, and SMA200 respectively, with the BBLG price moving below the 50-day SMA on current market day. Bone Biologics Corp (BBLG) stock is up 65.79% over the week and 28.57% over the past month. Its price is -58.19% year-to-date and -66.30% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/30/2024, with the company’s earnings per share (EPS) of -4.88 above consensus estimates by 19.44. The company’s next earnings report forecasts estimating quarterly EPS at -0.6 and -3.17 for whole year.
To reach the target analysts have set, the stock logically needs to grow 88.72 percent from here.
Outstanding shares total 0.53M with insiders holding 6.07% of the shares and institutional holders owning 3.74% of the company’s common stock. The company has a return on investment of -175.98% and return on equity of -119.03%. Price to book ratio is 0.85.
